Cargando…

Impact of lenvatinib-induced proteinuria and renal dysfunction in patients with thyroid cancer

BACKGROUND: Proteinuria is the most frequent adverse event of lenvatinib use. However, the association between lenvatinib-induced proteinuria and renal dysfunction remains unclear. METHODS: We retrospectively reviewed medical records of patients with thyroid cancer without proteinuria treated with l...

Descripción completa

Detalles Bibliográficos
Autores principales:	Shibutani, Yuma, Suzuki, Shinya, Sagara, Atsunobu, Enokida, Tomohiro, Okano, Susumu, Fujisawa, Takao, Sato, Fumiaki, Yumoto, Tetsuro, Sano, Motohiko, Kawasaki, Toshikatsu, Tahara, Makoto
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2023
Materias:	Oncology
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10043443/ https://www.ncbi.nlm.nih.gov/pubmed/36998435 http://dx.doi.org/10.3389/fonc.2023.1154771

Ejemplares similares

Planned drug holidays during treatment with lenvatinib for radioiodine-refractory differentiated thyroid cancer: a retrospective study
por: Matsuyama, Chihiro, et al.
Publicado: (2023)

Paclitaxel Plus Cetuximab as 1st Line Chemotherapy in Platinum-Based Chemoradiotherapy-Refractory Patients With Squamous Cell Carcinoma of the Head and Neck
por: Enokida, Tomohiro, et al.
Publicado: (2018)

A pharmacist-led opioid de-escalation program after completion of chemoradiotherapy in locally advanced head and neck cancer
por: Horinouchi, Ai, et al.
Publicado: (2023)

Combination Treatment With Paclitaxel, Carboplatin, and Cetuximab (PCE) as First-Line Treatment in Patients With Recurrent and/or Metastatic Nasopharyngeal Carcinoma
por: Ueda, Yuri, et al.
Publicado: (2020)

Incidence and Risk Factors of Hypomagnesemia in Head and Neck Cancer Patients Treated with Cetuximab
por: Enokida, Tomohiro, et al.
Publicado: (2016)

Predictive Value of Cetuximab-Induced Skin Toxicity in Recurrent or Metastatic Squamous Cell Carcinoma of the Head and NECK
por: Uozumi, Shinya, et al.
Publicado: (2018)

Impact of outpatient pharmacy interventions on management of thyroid patients receiving lenvatinib
por: Suzuki, Shinya, et al.
Publicado: (2020)

Impact of air temperature and drug concentration on liquid emission from elastomeric pumps
por: Abe, Tomoya, et al.
Publicado: (2021)

A phase I, single-center, open-label study of RM-1929 photoimmunotherapy in Japanese patients with recurrent head and neck squamous cell carcinoma
por: Tahara, Makoto, et al.
Publicado: (2021)

Induction chemotherapy with paclitaxel, carboplatin and cetuximab for locoregionally advanced nasopharyngeal carcinoma: A single-center, retrospective study
por: Takeshita, Naohiro, et al.
Publicado: (2022)

Lenvatinib for Anaplastic Thyroid Cancer
por: Tahara, Makoto, et al.
Publicado: (2017)

Combination chemotherapy with taxane and platinum in patients with salivary gland carcinoma: a retrospective study of docetaxel plus cisplatin and paclitaxel plus carboplatin
por: Onaga, Ryutaro, et al.
Publicado: (2023)

Validation of a Liquid Chromatography-Tandem Mass Spectrometric Assay for Quantitative Analysis of Lenvatinib in Human Plasma
por: Ogawa-Morita, Tomoko, et al.
Publicado: (2017)

Retrospective analysis of premedication, glucocorticosteroids, and H(1)-antihistamines for preventing infusion reactions associated with cetuximab treatment of patients with head and neck cancer
por: Ikegawa, Kiwako, et al.
Publicado: (2017)

A Case Series on Pain Accompanying Photoimmunotherapy for Head and Neck Cancer
por: Shibutani, Yuma, et al.
Publicado: (2023)

Effect of different shielding conditions on the stability of Cisplatin
por: Abe, Tomoya, et al.
Publicado: (2020)

Electrochemotherapy in the Treatment of Head and Neck Cancer: Current Conditions and Future Directions
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Management of VEGFR-Targeted TKI for Thyroid Cancer
por: Enokida, Tomohiro, et al.
Publicado: (2021)

Optimal use of lenvatinib in the treatment of advanced thyroid cancer
por: Takahashi, Shunji, et al.
Publicado: (2017)

A multicenter phase II trial of paclitaxel, carboplatin, and cetuximab followed by chemoradiotherapy in patients with unresectable locally advanced squamous cell carcinoma of the head and neck
por: Enokida, Tomohiro, et al.
Publicado: (2020)

Thrombotic Microangiopathy with Severe Proteinuria Induced by Lenvatinib for Radioactive Iodine-Refractory Papillary Thyroid Carcinoma
por: Hyogo, Yasuko, et al.
Publicado: (2018)

Thrombotic Microangiopathy, Podocytopathy, and Damage to the Renal Tubules with Severe Proteinuria and Acute Renal Dysfunction Induced by Lenvatinib
por: Nakashima, Saki, et al.
Publicado: (2022)

Development of a novel drug information provision system for Kampo medicine using natural language processing technology
por: Maeda-Minami, Ayako, et al.
Publicado: (2023)

Evaluation of the impact of a flowchart-type leaflet for cancer inpatients
por: Suzuki, Shinya, et al.
Publicado: (2014)

Repeated Perforation of the Gallbladder in a Patient with Hepatocellular Carcinoma Receiving Lenvatinib
por: Honda, Shuya, et al.
Publicado: (2019)

Gene expression profiling to predict recurrence of advanced squamous cell carcinoma of the tongue: discovery and external validation
por: Enokida, Tomohiro, et al.
Publicado: (2017)

Salvage Reconstructive Surgery During Nivolumab Therapy for a Patient With Hypopharyngeal Cancer
por: Tsushima, Nayuta, et al.
Publicado: (2020)

EGFR inhibition reverses resistance to lenvatinib in hepatocellular carcinoma cells
por: He, Xiaoping, et al.
Publicado: (2022)

Terahertz spectra of proteinuria and non-proteinuria
por: Xue, Zhenrui, et al.
Publicado: (2023)

Nasogastric administration of lenvatinib solution in a mechanically ventilated patient with rapidly growing anaplastic thyroid cancer
por: Kawano, Fumiaki, et al.
Publicado: (2020)

Reversal of P‐Glycoprotein‐mediated Paclitaxel Resistance by New Synthetic Isoprenoids in Human Bladder Cancer Cell Line
por: Enokida, Hideki, et al.
Publicado: (2002)

Lenvatinib for the Treatment of Radioiodine-Refractory Differentiated Thyroid Cancer: Treatment Optimization for Maximum Clinical Benefit
por: Wirth, Lori J, et al.
Publicado: (2022)

Safety and Effectiveness of Lenvatinib in 594 Patients with Unresectable Thyroid Cancer in an All-Case Post-Marketing Observational Study in Japan
por: Takahashi, Shunji, et al.
Publicado: (2020)

Characterization of Tumor Size Changes Over Time From the Phase 3 Study of Lenvatinib in Thyroid Cancer
por: Robinson, Bruce, et al.
Publicado: (2016)

Defining Radioiodine-Refractory Differentiated Thyroid Cancer: Efficacy and Safety of Lenvatinib by Radioiodine-Refractory Criteria in the SELECT Trial
por: Kiyota, Naomi, et al.
Publicado: (2017)

Curcumin-Mediated Resistance to Lenvatinib via EGFR Signaling Pathway in Hepatocellular Carcinoma
por: Miyazaki, Katsuki, et al.
Publicado: (2023)

5-Fluorouracil Induces Diarrhea with Changes in the Expression of Inflammatory Cytokines and Aquaporins in Mouse Intestines
por: Sakai, Hiroyasu, et al.
Publicado: (2013)

Proteinuria in Diabetes
por: Thomas, Stephen, et al.
Publicado: (2000)

Safety survey on infusion reaction and cardiac dysfunction when switching from reference trastuzumab (HERCEPTIN(®)) to biosimilar trastuzumab (Trastuzumab‑NK) in the treatment of HER2‑positive breast cancer
por: Abe, Tomoya, et al.
Publicado: (2023)

Lenvatinib rechallenge in a patient with advanced thymic carcinoma: A case report
por: Terashima, Yuto, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_60c3d21c04tv7ov0f7jjvv791h